Psychoneuroimmunology

Psychoneuroimmunology (PNI), also referred to as psychoendoneuroimmunology (PENI) or psychoneuroendocrinoimmunology (PNEI), is the study of the interaction between psychological processes and the nervous and immune systems of the human body.[1][2] It is a subfield of psychosomatic medicine. PNI takes an interdisciplinary approach, incorporating psychology, neuroscience, immunology, physiology, genetics, pharmacology, molecular biology, psychiatry, behavioral medicine, infectious diseases, endocrinology, and rheumatology.

The main interests of PNI are the interactions between the nervous and immune systems and the relationships between mental processes and health. PNI studies, among other things, the physiological functioning of the neuroimmune system in health and disease; disorders of the neuroimmune system (autoimmune diseases; hypersensitivities; immune deficiency); and the physical, chemical and physiological characteristics of the components of the neuroimmune system in vitro, in situ, and in vivo.

History

Interest in the relationship between psychiatric syndromes or symptoms and immune function has been a consistent theme since the beginning of modern medicine.

Claude Bernard, the father of modern physiology, with his pupils

Claude Bernard, a French physiologist of the Muséum national d'Histoire naturelle (National Museum of Natural History in English), formulated the concept of the milieu interieur in the mid-1800s. In 1865, Bernard described the perturbation of this internal state: "... there are protective functions of organic elements holding living materials in reserve and maintaining without interruption humidity, heat and other conditions indispensable to vital activity. Sickness and death are only a dislocation or perturbation of that mechanism" (Bernard, 1865). Walter Cannon, a professor of physiology at Harvard University coined the commonly used term, homeostasis, in his book The Wisdom of the Body, 1932, from the Greek word homoios, meaning similar, and stasis, meaning position. In his work with animals, Cannon observed that any change of emotional state in the beast, such as anxiety, distress, or rage, was accompanied by total cessation of movements of the stomach (Bodily Changes in Pain, Hunger, Fear and Rage, 1915). These studies looked into the relationship between the effects of emotions and perceptions on the autonomic nervous system, namely the sympathetic and parasympathetic responses that initiated the recognition of the freeze, fight or flight response. His findings were published from time to time in professional journals, then summed up in book form in The Mechanical Factors of Digestion, published in 1911.

Bust of Hans Selye at Selye János University, Komárno, Slovakia

Hans Selye, a student of Johns Hopkins University and McGill University, and a researcher at Université de Montréal, experimented with animals by putting them under different physical and mental adverse conditions and noted that under these difficult conditions the body consistently adapted to heal and recover. Several years of experimentation that formed the empiric foundation of Selye's concept of the General Adaptation Syndrome. This syndrome consists of an enlargement of the adrenal gland, atrophy of the thymus, spleen, and other lymphoid tissue, and gastric ulcerations.

Selye describes three stages of adaptation, including an initial brief alarm reaction, followed by a prolonged period of resistance, and a terminal stage of exhaustion and death. This foundational work led to a rich line of research on the biological functioning of glucocorticoids.[3]

Mid-20th century studies of psychiatric patients reported immune alterations in psychotic individuals, including lower numbers of lymphocytes[4][5] and poorer antibody response to pertussis vaccination, compared with nonpsychiatric control subjects.[6] In 1964, George F. Solomon, from the University of California in Los Angeles, and his research team coined the term "psychoimmunology" and published a landmark paper: "Emotions, immunity, and disease: a speculative theoretical integration."[7]

Origins

In 1975, Robert Ader and Nicholas Cohen, at the University of Rochester, advanced PNI with their demonstration of classic conditioning of immune function, and they subsequently coined the term "psychoneuroimmunology".[8][9] Ader was investigating how long conditioned responses (in the sense of Pavlov's conditioning of dogs to drool when they heard a bell ring) might last in laboratory rats. To condition the rats, he used a combination of saccharin-laced water (the conditioned stimulus) and the drug Cytoxan, which unconditionally induces nausea and taste aversion and suppression of immune function. Ader was surprised to discover that after conditioning, just feeding the rats saccharin-laced water was associated with the death of some animals and he proposed that they had been immunosuppressed after receiving the conditioned stimulus. Ader (a psychologist) and Cohen (an immunologist) directly tested this hypothesis by deliberately immunizing conditioned and unconditioned animals, exposing these and other control groups to the conditioned taste stimulus, and then measuring the amount of antibody produced. The highly reproducible results revealed that conditioned rats exposed to the conditioned stimulus were indeed immunosuppressed. In other words, a signal via the nervous system (taste) was affecting immune function. This was one of the first scientific experiments that demonstrated that the nervous system can affect the immune system.

In the 1970s, Hugo Besedovsky, Adriana del Rey and Ernst Sorkin, working in Switzerland, reported multi-directional immune-neuro-endocrine interactions, since they show that not only the brain can influence immune processes but also the immune response itself can affect the brain and neuroendocrine mechanisms. They found that the immune responses to innocuous antigens triggers an increase in the activity of hypothalamic neurons[10][11] and hormonal and autonomic nerve responses that are relevant for immunoregulation and are integrated at brain levels (see review[12]). On these bases, they proposed that the immune system acts as a sensorial receptor organ that, besides its peripheral effects, can communicate to the brain and associated neuro-endocrine structures its state of activity.[11] These investigators also identified products from immune cells, later characterized as cytokines, that mediate this immune-brain communication[13] (more references in [12]).

In 1981, David L. Felten, then working at the Indiana University School of Medicine, and his colleague JM Williams, discovered a network of nerves leading to blood vessels as well as cells of the immune system. The researchers also found nerves in the thymus and spleen terminating near clusters of lymphocytes, macrophages, and mast cells, all of which help control immune function. This discovery provided one of the first indications of how neuro-immune interaction occurs.

Ader, Cohen, and Felten went on to edit the groundbreaking book Psychoneuroimmunology in 1981, which laid out the underlying premise that the brain and immune system represent a single, integrated system of defense.

In 1985, research by neuropharmacologist Candace Pert, of the National Institutes of Health at Georgetown University, revealed that neuropeptide-specific receptors are present on the cell walls of both the brain and the immune system.[14][15] The discovery that neuropeptides and neurotransmitters act directly upon the immune system shows their close association with emotions and suggests mechanisms through which emotions, from the limbic system, and immunology are deeply interdependent. Showing that the immune and endocrine systems are modulated not only by the brain but also by the central nervous system itself affected the understanding of emotions, as well as disease.

Contemporary advances in psychiatry, immunology, neurology, and other integrated disciplines of medicine has fostered enormous growth for PNI. The mechanisms underlying behaviorally induced alterations of immune function, and immune alterations inducing behavioral changes, are likely to have clinical and therapeutic implications that will not be fully appreciated until more is known about the extent of these interrelationships in normal and pathophysiological states.

The immune-brain loop
Further information: Cell signaling networks and Signal transduction

PNI research looks for the exact mechanisms by which specific neuroimmune effects are achieved. Evidence for nervous-immunological interactions exist at multiple biological levels.

The immune system and the brain communicate through signaling pathways. The brain and the immune system are the two major adaptive systems of the body. Two major pathways are involved in this cross-talk: the Hypothalamic-pituitary-adrenal axis (HPA axis), and the sympathetic nervous system (SNS), via the sympathetic-adrenal-medullary axis (SAM axis). The activation of SNS during an immune response might be aimed to localize the inflammatory response.

The body's primary stress management system is the HPA axis. The HPA axis responds to physical and mental challenge to maintain homeostasis in part by controlling the body's cortisol level. Dysregulation of the HPA axis is implicated in numerous stress-related diseases, with evidence from meta-analyses indicating that different types/duration of stressors and unique personal variables can shape the HPA response.[16] HPA axis activity and cytokines are intrinsically intertwined: inflammatory cytokines stimulate adrenocorticotropic hormone (ACTH) and cortisol secretion, while, in turn, glucocorticoids suppress the synthesis of proinflammatory cytokines.

Molecules called pro-inflammatory cytokines, which include interleukin-1 (IL-1), Interleukin-2 (IL-2), interleukin-6 (IL-6), Interleukin-12 (IL-12), Interferon-gamma (IFN-Gamma) and tumor necrosis factor alpha (TNF-alpha) can affect brain growth as well as neuronal function. Circulating immune cells such as macrophages, as well as glial cells (microglia and astrocytes) secrete these molecules. Cytokine regulation of hypothalamic function is an active area of research for the treatment of anxiety-related disorders.[17]

Cytokines mediate and control immune and inflammatory responses. Complex interactions exist between cytokines, inflammation and the adaptive responses in maintaining homeostasis. Like the stress response, the inflammatory reaction is crucial for survival. Systemic inflammatory reaction results in stimulation of four major programs:[18]

These are mediated by the HPA axis and the SNS. Common human diseases such as allergy, autoimmunity, chronic infections and sepsis are characterized by a dysregulation of the pro-inflammatory versus anti-inflammatory and T helper (Th1) versus (Th2) cytokine balance. Recent studies show pro-inflammatory cytokine processes take place during depression, mania and bipolar disease, in addition to autoimmune hypersensitivity and chronic infections.[19]

Chronic secretion of stress hormones, glucocorticoids (GCs) and catecholamines (CAs), as a result of disease, may reduce the effect of neurotransmitters, including serotonin, norepinephrine and dopamine, or other receptors in the brain, thereby leading to the dysregulation of neurohormones.[19] Under stimulation, norepinephrine is released from the sympathetic nerve terminals in organs, and the target immune cells express adrenoreceptors. Through stimulation of these receptors, locally released norepinephrine, or circulating catecholamines such as epinephrine, affect lymphocyte traffic, circulation, and proliferation, and modulate cytokine production and the functional activity of different lymphoid cells.

Glucocorticoids also inhibit the further secretion of corticotropin-releasing hormone from the hypothalamus and ACTH from the pituitary (negative feedback). Under certain conditions stress hormones may facilitate inflammation through induction of signaling pathways and through activation of the Corticotropin-releasing hormone.

These abnormalities and the failure of the adaptive systems to resolve inflammation affect the well-being of the individual, including behavioral parameters, quality of life and sleep, as well as indices of metabolic and cardiovascular health, developing into a "systemic anti-inflammatory feedback" and/or "hyperactivity" of the local pro-inflammatory factors which may contribute to the pathogenesis of disease.

This systemic or neuro-inflammation and neuroimmune activation have been shown to play a role in the etiology of a variety of neurodegenerative disorders such as Parkinson's and Alzheimer's disease, multiple sclerosis, pain, and AIDS-associated dementia. However, cytokines and chemokines also modulate central nervous system (CNS) function in the absence of overt immunological, physiological, or psychological challenges.[20]

Psychoneuroimmunological effects

There are now sufficient data to conclude that immune modulation by psychosocial stressors and/or interventions can lead to actual health changes. Although changes related to infectious disease and wound healing have provided the strongest evidence to date, the clinical importance of immunological dysregulation is highlighted by increased risks across diverse conditions and diseases. For example, stressors can produce profound health consequences. In one epidemiological study, all-cause mortality increased in the month following a severe stressor – the death of a spouse.[21] Theorists propose that stressful events trigger cognitive and affective responses which, in turn, induce sympathetic nervous system and endocrine changes, and these ultimately impair immune function.[22][23] Potential health consequences are broad, but include rates of infection[24][25] HIV progression[26][27] cancer incidence and progression,[21][28][29] and high rates of infant mortality.[30][31]

Understanding stress and immune function

Stress is thought to affect immune function through emotional and/or behavioral manifestations such as anxiety, fear, tension, anger and sadness and physiological changes such as heart rate, blood pressure, and sweating. Researchers have suggested that these changes are beneficial if they are of limited duration,[22] but when stress is chronic, the system is unable to maintain equilibrium or homeostasis; the body remains in a state of arousal, where digestion is slower to reactivate or does not reactivate properly, often resulting in indigestion. Furthermore, blood pressure stays at higher levels.

In one of the earlier PNI studies, which was published in 1960, subjects were led to believe that they had accidentally caused serious injury to a companion through misuse of explosives.[32] Since then decades of research resulted in two large meta-analyses, which showed consistent immune dysregulation in healthy people who are experiencing stress.

In the first meta-analysis by Herbert and Cohen in 1993,[33] they examined 38 studies of stressful events and immune function in healthy adults. They included studies of acute laboratory stressors (e.g. a speech task), short-term naturalistic stressors (e.g. medical examinations), and long-term naturalistic stressors (e.g. divorce, bereavement, caregiving, unemployment). They found consistent stress-related increases in numbers of total white blood cells, as well as decreases in the numbers of helper T cells, suppressor T cells, and cytotoxic T cells, B cells, and natural killer cells (NK). They also reported stress-related decreases in NK and T cell function, and T cell proliferative responses to phytohaemagglutinin [PHA] and concanavalin A [Con A]. These effects were consistent for short-term and long-term naturalistic stressors, but not laboratory stressors.

In the second meta-analysis by Zorrilla et al. in 2001,[34] they replicated Herbert and Cohen's meta-analysis. Using the same study selection procedures, they analyzed 75 studies of stressors and human immunity. Naturalistic stressors were associated with increases in number of circulating neutrophils, decreases in number and percentages of total T cells and helper T cells, and decreases in percentages of natural killer cell (NK) cells and cytotoxic T cell lymphocytes. They also replicated Herbert and Cohen's finding of stress-related decreases in NKCC and T cell mitogen proliferation to phytohaemagglutinin (PHA) and concanavalin A (Con A).

A study done by the American Psychological Association did an experiment on rats, where they applied electrical shocks to a rat, and saw how interleukin-1 was released directly into the brain. Interleukin-1 is the same cytokine released when a macrophage chews on a bacterium, which then travels up your vagus nerve, creating a state of heightened immune activity, and behavioral changes.[35]

More recently, there has been increasing interest in the links between interpersonal stressors and immune function. For example, marital conflict, loneliness, caring for a person with a chronic medical condition, and other forms on interpersonal stress dysregulate immune function.[36]

Communication between the brain and immune system
  • Stimulation of brain sites alters immunity (stressed animals have altered immune systems).
  • Damage to brain hemispheres alters immunity (hemispheric lateralization effects).[37]
  • Immune cells produce cytokines that act on the CNS.
  • Immune cells respond to signals from the CNS.

Communication between neuroendocrine and immune system
  • Glucocorticoids and catecholamines influence immune cells.[38][39]
  • Hypothalamic Pituitary Adrenal axis releases the needed hormones to support the immune system.[40]
  • Activity of the immune system is correlated with neurochemical/neuroendocrine activity of brain cells.

Connections between glucocorticoids and immune system
  • Anti-inflammatory hormones that enhance the organism's response to a stressor.
  • Prevent the overreaction of the body's own defense system.
  • Overactivation of glucocorticoid receptors can lead to health risks.[41]
  • Regulators of the immune system.
  • Affect cell growth, proliferation and differentiation.
  • Cause immunosuppression which can lead to an extended amount of time fighting off infections.[41]
  • High basal levels of cortisol are associated with a higher risk of infection.[41]
  • Suppress cell adhesion, antigen presentation, chemotaxis and cytotoxicity.
  • Increase apoptosis.

Corticotropin-releasing hormone (CRH)

Release of corticotropin-releasing hormone (CRH) from the hypothalamus is influenced by stress.[42]

  • CRH is a major regulator of the HPA axis/stress axis.
  • CRH Regulates secretion of Adrenocorticotropic hormone (ACTH).
  • CRH is widely distributed in the brain and periphery
  • CRH also regulates the actions of the Autonomic nervous system ANS and immune system.

Furthermore, stressors that enhance the release of CRH suppress the function of the immune system; conversely, stressors that depress CRH release potentiate immunity.

  • Central mediated since peripheral administration of CRH antagonist does not affect immunosuppression.
  • HPA axis/stress axis responds consistently to stressors that are new, unpredictable and that have low-perceived control.[42]
  • As cortisol reaches an appropriate level in response to the stressor, it deregulates the activity of the hippocampus, hypothalamus, and pituitary gland which results in less production of cortisol.[42]

Relationships between prefrontal cortex activation and cellular senescence
  • Psychological stress is regulated by the prefrontal cortex (PFC)
  • The PFC modulates vagal activity[43]
  • Prefrontally modulated and vagally mediated cholinergic input to the spleen reduces inflammatory responses[44]
  • PFC-ANS-Spleen axis activity has consequences for reactive oxygen species-induced telomere damage[45][46]

Pharmaceutical advances
Further information: Neuropsychopharmacology

Glutamate agonists, cytokine inhibitors, vanilloid-receptor agonists, catecholamine modulators, ion-channel blockers, anticonvulsants, GABA agonists (including opioids and cannabinoids), COX inhibitors, acetylcholine modulators, melatonin analogs (such as Ramelton), adenosine receptor antagonists and several miscellaneous drugs (including biologics like Passiflora edulis) are being studied for their psychoneuroimmunological effects.

For example, SSRIs, SNRIs and tricyclic antidepressants acting on serotonin, norepinephrine, dopamine and cannabinoid receptors have been shown to be immunomodulatory and anti-inflammatory against pro-inflammatory cytokine processes, specifically on the regulation of IFN-gamma and IL-10, as well as TNF-alpha and IL-6 through a psychoneuroimmunological process.[47][48][49][50] Antidepressants have also been shown to suppress TH1 upregulation.[47][48][49][51][52]

Tricyclic and dual serotonergic-noradrenergic reuptake inhibition by SNRIs (or SSRI-NRI combinations), have also shown analgesic properties additionally.[53][54] According to recent evidences antidepressants also seem to exert beneficial effects in experimental autoimmune neuritis in rats by decreasing Interferon-beta (IFN-beta) release or augmenting NK activity in depressed patients.[17]

These studies warrant investigation of antidepressants for use in both psychiatric and non-psychiatric illness and that a psychoneuroimmunological approach may be required for optimal pharmacotherapy in many diseases.[55] Future antidepressants may be made to specifically target the immune system by either blocking the actions of pro-inflammatory cytokines or increasing the production of anti-inflammatory cytokines.[56]

The endocannabinoid system appears to play a significant role in the mechanism of action of clinically effective and potential antidepressants and may serve as a target for drug design and discovery.[50] The endocannabinoid-induced modulation of stress-related behaviors appears to be mediated, at least in part, through the regulation of the serotoninergic system, by which cannabinoid CB1 receptors modulate the excitability of dorsal raphe serotonin neurons.[57] Data suggest that the endocannabinoid system in cortical and subcortical structures is differentially altered in an animal model of depression and that the effects of chronic, unpredictable stress (CUS) on CB1 receptor binding site density are attenuated by antidepressant treatment while those on endocannabinoid content are not.

The increase in amygdalar CB1 receptor binding following imipramine treatment is consistent with prior studies which collectively demonstrate that several treatments which are beneficial to depression, such as electroconvulsive shock and tricyclic antidepressant treatment, increase CB1 receptor activity in subcortical limbic structures, such as the hippocampus, amygdala and hypothalamus. And preclinical studies have demonstrated the CB1 receptor is required for the behavioral effects of noradrenergic based antidepressants but is dispensable for the behavioral effect of serotonergic based antidepressants.[58][59]

Extrapolating from the observations that positive emotional experiences boost the immune system, Roberts speculates that intensely positive emotional experiences —sometimes brought about during mystical experiences occasioned by psychedelic medicines—may boost the immune system powerfully. Research on salivary IgA supports this hypothesis, but experimental testing has not been done.[60]

See also

References
  1. Michael Irwin, Kavita Vedhara (2005). Human Psychoneuroimmunology. Oxford University Press. ISBN 978-0-19-856884-1.
  2. Segerstrom, Suzanne C., ed. (2012). The Oxford handbook of psychoneuroimmunology. New York: Oxford University Press. ISBN 9780195394399. OCLC 775894214.
  3. Neylan Thomas C (1998). "Hans Selye and the Field of Stress Research". J Neuropsychiatry Clin Neurosci. 10 (2): 230. doi:10.1176/jnp.10.2.230.
  4. Freeman H, Elmadjian F (1947). "The relationship between blood sugar and lymphocyte levels in normal and psychotic subjects". Psychosom Med. 9 (4): 226–33. doi:10.1097/00006842-194707000-00002. PMID 20260255. S2CID 35806157.
  5. Phillips L, Elmadjian F (1947). "A Rorschach tension score and the diurnal lymphocyte curve in psychotic subjects". Psychosom Med. 9 (6): 364–71. doi:10.1097/00006842-194711000-00002. PMID 18913449. S2CID 2210570.
  6. Vaughan WT, Sullivan JC, Elmadjian F (1949). "Immunity and schizophrenia". Psychosom Med. 11 (6): 327–33. doi:10.1097/00006842-194911000-00001. PMID 15406182. S2CID 30835205.
  7. Solomon GF, Moos RH. Emotions, immunity, and disease: a speculative theoretical integration. Arch Gen Psychiatry 1964; 11: 657–74
  8. R Ader and N Cohen. Behaviorally conditioned immunosuppression. Psychosomatic Medicine, Vol 37, Issue 4 333-340
  9. "Robert Ader, Founder of Psychoneuroimmunology, Dies". University of Rochester Medical Center. 2011-12-20. Retrieved 2011-12-20.
  10. Besedovsky, H.; Sorkin, E.; Felix, D.; Haas, H. (May 1977). "Hypothalamic changes during the immune response". European Journal of Immunology. 7 (5): 323–325. doi:10.1002/eji.1830070516. ISSN 0014-2980. PMID 326564. S2CID 224774815.
  11. Besedovsky, H.; del Rey, A.; Sorkin, E.; Da Prada, M.; Burri, R.; Honegger, C. (1983-08-05). "The immune response evokes changes in brain noradrenergic neurons". Science. 221 (4610): 564–566. Bibcode:1983Sci...221..564B. doi:10.1126/science.6867729. ISSN 0036-8075. PMID 6867729.
  12. Besedovsky, Hugo O.; Rey, Adriana Del (January 2007). "Physiology of psychoneuroimmunology: a personal view". Brain, Behavior, and Immunity. 21 (1): 34–44. doi:10.1016/j.bbi.2006.09.008. ISSN 0889-1591. PMID 17157762. S2CID 24279481.
  13. Besedovsky, H.; del Rey, A.; Sorkin, E.; Dinarello, C. A. (1986-08-08). "Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones". Science. 233 (4764): 652–654. Bibcode:1986Sci...233..652B. doi:10.1126/science.3014662. ISSN 0036-8075. PMID 3014662.
  14. Pert CB, Ruff MR, Weber RJ, Herkenham M. "Neuropeptides and their receptors: a psychosomatic network" J Immunol 1985 Aug;135(2 Suppl):820s-826s
  15. Ruff M, Schiffmann E, Terranova V, Pert CB (Dec 1985). "Neuropeptides are chemoattractants for human tumor cells and monocytes: a possible mechanism for metastasis". Clin Immunol Immunopathol. 37 (3): 387–96. doi:10.1016/0090-1229(85)90108-4. PMID 2414046.
  16. Miller, Gregory E.; Chen, Edith; Zhou, Eric S. (January 2007). "If it goes up, must it come down? Chronic stress and the hypothalamic-pituitary-adrenocortical axis in humans". Psychological Bulletin. 133 (1): 25–45. doi:10.1037/0033-2909.133.1.25. PMID 17201569.
  17. Covelli V, Passeri ME, Leogrande D, Jirillo E, Amati L (2005). "Drug targets in stress-related disorders". Curr. Med. Chem. 12 (15): 1801–9. doi:10.2174/0929867054367202. PMID 16029148.
  18. Elenkov IJ (2005). "Cytokine dysregulation, inflammation and well-being". Neuroimmunomodulation. 12 (5): 255–69. doi:10.1159/000087104. PMID 16166805. S2CID 39185155.
  19. Hall, Rudolph (2011-06-11). Narcissistic behavior in the postmodern era : the study of neuropsychology. p. 136. ISBN 9781462884193.
  20. Functional Links between the Immune System, Brain Function and Behavior
  21. Kaprio J.; Koskenvuo M.; Rita H. (1987). "Mortality after bereavement: a prospective study of 95,647 widowed persons". American Journal of Public Health. 77 (3): 283–7. doi:10.2105/ajph.77.3.283. PMC 1646890. PMID 3812831.
  22. Chrousos, G. P. and Gold, P. W. (1992). The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA 267(Mar 4), 1244-52.
  23. Glaser, R. and Kiecolt-Glaser, J. K. (1994). Handbook of Human Stress and Immunity. San Diego: Academic Press.
  24. Cohen S.; Tyrrell D. A.; Smith A. P. (1991). "Psychological stress and susceptibility to the common cold". The New England Journal of Medicine. 325 (9): 606–12. doi:10.1056/nejm199108293250903. PMID 1713648.
  25. Cohen S.; Williamson G. M. (1991). "Stress and infectious disease in humans". Psychological Bulletin. 109 (1): 5–24. doi:10.1037/0033-2909.109.1.5. PMID 2006229.
  26. Leserman J.; Petitto J. M.; Golden R. N.; Gaynes B. N.; Gu H.; Perkins D. O.; Silva S. G.; Folds J. D.; Evans D. L. (2000). "Impact of stressful life events, depression, social support, coping, and cortisol on progression to AIDS". The American Journal of Psychiatry. 157 (8): 1221–8. doi:10.1176/appi.ajp.157.8.1221. PMID 10910783.
  27. Leserman J.; Jackson E. D.; Petitto J. M.; Golden R. N.; Silva S. G.; Perkins D. O.; Cai J.; Folds J. D.; Evans D. L. (1999). "Progression to AIDS: the effects of stress, depressive symptoms, and social support". Psychosomatic Medicine. 61 (3): 397–406. doi:10.1097/00006842-199905000-00021. PMID 10367622.
  28. Andersen B. L.; Kiecolt-Glaser J. K.; Glaser R. (1994). "A biobehavioral model of cancer stress and disease course". American Psychologist. 49 (5): 389–404. doi:10.1037/0003-066x.49.5.389. PMC 2719972. PMID 8024167.
  29. Kiecolt-Glaser J. K.; Glaser R. (1999). "Psychoneuroimmunology and cancer: fact or fiction?". European Journal of Cancer. 35 (11): 1603–7. doi:10.1016/s0959-8049(99)00197-5. PMID 10673969.
  30. Osel, Joseph, D. (2008). "Being (Born) Black in America: Perceived Discrimination & African American Infant Mortality", The Evergreen State College Symposium on Psychoneuroimmunology; SSRN.
  31. Collins J. W.; David R.; Handler A.; Wall S.; Andes S. (2004). "Very low birthweight in African American infants: The role of maternal exposure to interpersonal racial discrimination". American Journal of Public Health. 94 (12): 2132–2138. doi:10.2105/ajph.94.12.2132. PMC 1448603. PMID 15569965.
  32. McDonald RD, Yagi K (1960). "A note on eosinopenia as an index of psychological stress". Psychosom Med. 2 (22): 149–50. doi:10.1097/00006842-196003000-00007. S2CID 147391585.
  33. Herbert TB, Cohen S (1993). "Stress and immunity in humans: a meta-analytic review". Psychosom. Med. 55 (4): 364–379. CiteSeerX 10.1.1.125.6544. doi:10.1097/00006842-199307000-00004. PMID 8416086. S2CID 2025176.
  34. Zorrilla E. P.; Luborsky L.; McKay J. R.; Rosenthal R.; Houldin A.; Tax A.; McCorkle R.; Seligman D. A.; Schmidt K. (2001). "The relationship of depression and stressors to immunological assays: a meta-analytic review". Brain, Behavior, and Immunity. 15 (3): 199–226. doi:10.1006/brbi.2000.0597. PMID 11566046. S2CID 21106219.
  35. Azar, Beth (December 2001). "A new take on psychoneuroimmunology". Monitor on Psychology 32(11). American Psychological Association. Retrieved 2019-03-19.
  36. Jaremka, L.M. (2013). "Synergistic relationships among stress, depression, and troubled relationships: Insights from Psychoneuroimmunology". Depression and Anxiety. 30 (4): 288–296. doi:10.1002/da.22078. PMC 3816362. PMID 23412999.
  37. Sumner R.C.; Parton A.; Nowicky A.N.; Kishore U.; Gidron Y. (2011-12-15). "Hemispheric lateralisation and immune function: A systematic review of human research" (PDF). Journal of Neuroimmunology. 240–241: 1–12. doi:10.1016/j.jneuroim.2011.08.017. PMID 21924504. S2CID 10127202.
  38. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP (1998). "The pathophysiologic roles of interleukin-6 in human disease". Ann Intern Med. 128 (2): 127–137. doi:10.7326/0003-4819-128-2-199801150-00009. PMID 9441573. S2CID 37260638.
  39. Carlson, Neil R. (2013). Physiology of behavior (11th ed.). Boston: Pearson. p. 611. ISBN 978-0205239399.
  40. "Adrenal Fatigue 101 — Leah Hosburgh Leah Hosburgh Nutritonal Therapy". Leah Hosburgh. Retrieved 2020-12-07.
  41. Janicki-Deverts, Denise; Cohen, Sheldon; Turner, Ronald B.; Doyle, William J. (March 2016). "Basal salivary cortisol secretion and susceptibility to upper respiratory infection". Brain, Behavior, and Immunity. 53: 255–261. doi:10.1016/j.bbi.2016.01.013. PMC 4783177. PMID 26778776.
  42. Luecken, Linda; Gall, Linda; Nicolson, Nancy (2007). "Chapter 3: Measurement of Cortisol". Handbook of Physiological Research Methods in Health Psychology. SAGE Publications. pp. 37–44. ISBN 9781412926058.
  43. Thayer JF, Ahs F, Fredrikson M, et al. (December 2012). "A meta-analysis of heart rate variability and neuroimaging studies: implications for heart rate variability as a marker of stress and health". Neurosci Biobehav Rev. 36 (2): 747–756. doi:10.1016/j.neubiorev.2011.11.009. PMID 22178086. S2CID 2512272.
  44. Williams DP, Koenig J, Carnevali L, et al. (August 2019). "Heart rate variability and inflammation: A meta-analysis of human studies". Brain Behav. Immun. 80: 219–226. doi:10.1016/j.bbi.2019.03.009. PMID 30872091. S2CID 78091147.
  45. Ask TF, Lugo RG, Sütterlin S (October 2018). "The Neuro-Immuno-Senescence Integrative Model (NISIM) on the Negative Association Between Parasympathetic Activity and Cellular Senescence". Front. Neurosci. 12: 726. doi:10.3389/fnins.2018.00726. PMC 6194361. PMID 30369866.
  46. Epel E, Daubenmier J, Moskowitz JT, et al. (August 2009). "Can meditation slow rate of cellular aging? Cognitive stress, mindfulness, and telomeres". Ann N Y Acad Sci. 1172 (1): 34–53. Bibcode:2009NYASA1172...34E. doi:10.1111/j.1749-6632.2009.04414.x. PMC 3057175. PMID 19735238.
  47. Kubera M, Lin AH, Kenis G, Bosmans E, van Bockstaele D, Maes M (Apr 2001). "Anti-Inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio". J Clin Psychopharmacol. 21 (2): 199–206. doi:10.1097/00004714-200104000-00012. PMID 11270917. S2CID 43429490.
  48. Maes M."The immunoregulatory effects of antidepressants". Hum Psychopharmacol. 2001 Jan;16(1) 95-103
  49. Maes M, Kenis G, Kubera M, De Baets M, Steinbusch H, Bosmans E."The negative immunoregulatory effects of fluoxetine in relation to the cAMP-dependent PKA pathway". Int Immunopharmacol. 2005 Mar;5(3) 609-18.
  50. Smaga, Irena; Bystrowska, Beata; Gawliński, Dawid; Pomierny, Bartosz; Stankowicz, Piotr; Filip, Małgorzata (2014). "Antidepressants and Changes in Concentration of Endocannabinoids and N-Acylethanolamines in Rat Brain Structures". Neurotoxicity Research. 26 (2): 190–206. doi:10.1007/s12640-014-9465-0. ISSN 1029-8428. PMC 4067538. PMID 24652522.
  51. Diamond M, Kelly JP, Connor TJ (Oct 2006). "Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade". Eur Neuropsychopharmacol. 16 (7): 481–90. doi:10.1016/j.euroneuro.2005.11.011. PMID 16388933. S2CID 12983560.
  52. Brustolim D, Ribeiro-dos-Santos R, Kast RE, Altschuler EL, Soares MB (Jun 2006). "A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice" (PDF). Int Immunopharmacol. 6 (6): 903–7. doi:10.1016/j.intimp.2005.12.007. PMID 16644475.
  53. Moulin DE, Clark AJ, Gilron I, Ware MA, Watson CP, Sessle BJ, Coderre T, Morley-Forster PK, Stinson J, Boulanger A, Peng P, Finley GA, Taenzer P, Squire P, Dion D, Cholkan A, Gilani A, Gordon A, Henry J, Jovey R, Lynch M, Mailis-Gagnon A, Panju A, Rollman GB, Velly A (Spring 2007). "Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society". Pain Res Manag. 12 (1): 13–21. doi:10.1155/2007/730785. PMC 2670721. PMID 17372630.
  54. Jones CK, Eastwood BJ, Need AB, Shannon HE (Dec 2006). "Analgesic effects of serotonergic, noradrenergic or dual reuptake inhibitors in the carrageenan test in rats: evidence for synergism between serotonergic and noradrenergic reuptake inhibition". Neuropharmacology. 51 (7–8): 1172–80. doi:10.1016/j.neuropharm.2006.08.005. PMID 17045620. S2CID 23871569.
  55. Kulmatycki KM, Jamali F (2006). "Drug disease interactions: role of inflammatory mediators in depression and variability in antidepressant drug response". J Pharm Pharm Sci. 9 (3): 292–306. PMID 17207413.
  56. O'Brien SM, Scott LV, Dinan TG (Aug 2004). "Cytokines: abnormalities in major depression and implications for pharmacological treatment". Hum Psychopharmacol. 19 (6): 397–403. doi:10.1002/hup.609. PMID 15303243. S2CID 11723122.
  57. Haj-Dahmane, Samir; Shen, Roh-Yu (September 2011). "Modulation of the Serotonin System by Endocannabinoid Signaling". Neuropharmacology. 61 (3): 414–420. doi:10.1016/j.neuropharm.2011.02.016. ISSN 0028-3908. PMC 3110547. PMID 21354188.
  58. Hill, Matthew N.; Carrier, Erica J.; McLaughlin, Ryan J.; Morrish, Anna C.; Meier, Sarah E.; Hillard, Cecilia J.; Gorzalka, Boris B. (September 2008). "Regional Alterations in the Endocannabinoid System in an Animal Model of Depression: Effects of Concurrent Antidepressant Treatment". Journal of Neurochemistry. 106 (6): 2322–2336. doi:10.1111/j.1471-4159.2008.05567.x. ISSN 0022-3042. PMC 2606621. PMID 18643796.
  59. Hill, Matthew N.; Barr, Alasdair M.; Ho, W.-S. Vanessa; Carrier, Erica J.; Gorzalka, Boris B.; Hillard, Cecilia J. (2007-10-01). "Electroconvulsive shock treatment differentially modulates cortical and subcortical endocannabinoid activity". Journal of Neurochemistry. 103 (1): 47–56. doi:10.1111/j.1471-4159.2007.04688.x. ISSN 1471-4159. PMID 17561935.
  60. Roberts, Thomas B. (2006). "Chapter 6. Do Entheogen-induced Mystical Experiences Boost the Immune System?: Psychedelics, Peak Experiences, and Wellness". Psychedelic Horizons. Westport, CT: Praeger/Greenwood.

Further reading
  • Berczi and Szentivanyi (2003). NeuroImmune Biology, Elsevier, ISBN 0-444-50851-1 (Written for the highly technical reader)
  • Goodkin, Karl, and Adriaan P. Visser, (eds), Psychoneuroimmunology: Stress, Mental Disorders, and Health, American Psychiatric Press, 2000, ISBN 0-88048-171-4, technical.
  • Maqueda, A. "Psychosomatic Medicine, Psychoneuroimmunology and Psychedelics", Multidisciplinary Association for Psychedelic Studies, Vol xxi No 1.
  • Ransohoff, Richard, et al. (eds), Universes in Delicate Balance: Chemokines and the Nervous System, Elsevier, 2002, ISBN 0-444-51002-8
  • Robert Ader, David L. Felten, Nicholas Cohen, Psychoneuroimmunology, 4th edition, 2 volumes, Academic Press, (2006), ISBN 0-12-088576-X
  • Hafner Mateja, Ihan Alojz (2014). AWAKENING: Psyche in search of the lost Eros - psychoneuroimmunology, Alpha Center d.o.o., Institute for preventive medicine, ISBN 978-961-6070-26-3.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.